News

First Health Advisory Adds Health IT Leader David Finn to Deepen Digital Health Cyber Governance

Former CIO and CHIME leader David Finn joins First Health Advisory to support clients with policy changes facing the healthcare…

2 years ago

Neptune Announces Michael Cammarata’s Resignation Effective February 23, 2024

LAVAL, QC / ACCESSWIRE / March 4, 2024 / Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ:NEPT), today announced…

2 years ago

PharmaCord Announces Key Operational Appointments in Preparation for Its Next Phase of Growth

JEFFERSONVILLE, IN / ACCESSWIRE / March 4, 2024 / PharmaCord, a leading provider of patient services and commercialization solutions to…

2 years ago

Registration Is Now Open for Tribe Public’s Webinar Event “Revolutionizing Diabetes Care” Featuring Modular Medical CEO on Wednesday, March 6, 2024

Meet with Modular Medical CEO, Jeb BesserThere are more than 3 million individuals who use daily insulin to help with…

2 years ago

Ankle & Foot Centers of America Welcomes Dr. Cameron Neilson in Loganville, GA

Leading Podiatrist, Cameron Neilson, DPM, joins the Ankle & Foot Centers of America in Loganville, GA. Dr. Neilson is among…

2 years ago

Avant Brands Strengthens Board with the Addition of Tyson Macdonald

KELOWNA, BC / ACCESSWIRE / March 4, 2024 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer…

2 years ago

Intelligent Scopes Launches Helga AI-GEP™, an AI Platform for Gastroenterology with the Commencement of Validation of its AI Software Tool for Colon Cancer

NEW YORK and LONDON, March 04, 2024 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, specializing in state-of-the-art image enhancement and precision…

2 years ago

Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease

Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for…

2 years ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the…

2 years ago